Pamplona, Spain – Palobiofarma S.L. is pleased to announce the “last patient last visit” of the Phase II trial investigating the safety and preliminary efficacy of PBF-680 in moderate to severe COPD...
Pamplona, Spain – Palobiofarma S.L. is pleased to announce that the FDA and the EMA have granted Orphan Drug Designation to our novel therapeutic candidate, PBF-999, for the treatment of Prader-Willi...
Pamplona-Iruña, February 2, 2024.- Palobiofarma has closed a seven-million-euro investment round led by Inveready, through the Inveready Biotech IV fund, the public company Sodena and the company’s...
Pamplona, Spain November 6, 2023 Palobiofarma S.L. announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the company’s phosphodiesterase 10...
[Pamplona, Spain], [May 9th, 2023] – Palobiofarma S.L., a biopharmaceutical company dedicated to the discovery and development of innovative drugs, has enrolled the first three patients in a clinical study...
[May 4, 2023] – [Pamplona, Navarra] – The Foundation for Prader Willi Research (FPWR) has provided a new venture philanthropy award, in the form of a convertible loan, to Palobiofarma S.L., a Spanish...
Palobiofarma has received the approval of the European project that finances Phase II of the PBF-680 product in COPD. Additionally, it offers the possibility of partial financing of Phase III of PBF-680....
The Phase II trial studied the safety, tolerability, and preliminary efficacy of PBF-677 in patients with mild to moderate Ulcerative Colitis in flair condition on top of the standard of care Mesalazine...
The Phase II trial studies the safety, tolerability and preliminary efficacy of PBF-677 in patients with mild to moderate Ulcerative Colitis in flair condition on top of the standard of care (5-ASA). 30...
